Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta (γδ) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous γδ T-Cell Lymphomas

2017 ◽  
Vol 41 (2) ◽  
pp. 204-215 ◽  
Author(s):  
E. Dean Merrill ◽  
Rose Agbay ◽  
Roberto N. Miranda ◽  
Phyu P. Aung ◽  
Michael T. Tetzlaff ◽  
...  
Keyword(s):  
T Cell ◽  
Γδ T Cell ◽  
Gamma Delta ◽  
T Cell Lymphomas

scholarly journals Gamma-delta t-cell lymphomas

2014 ◽  
Vol 94 (3) ◽  
pp. 206-218 ◽  
Author(s):  
Marco Foppoli ◽  
Andrés J. M. Ferreri
Keyword(s):  
T Cell ◽  
Gamma Delta ◽  
T Cell Lymphomas ◽  
Gamma Delta T Cell

Gamma-delta T-cell lymphomas

2009 ◽  
Vol 6 (12) ◽  
pp. 707-717 ◽  
Author(s):  
Claudio Tripodo ◽  
Emilio Iannitto ◽  
Ada Maria Florena ◽  
Carlo Ennio Pucillo ◽  
Pier Paolo Piccaluga ◽  
...  
Keyword(s):  
T Cell ◽  
Gamma Delta ◽  
T Cell Lymphomas ◽  
Gamma Delta T Cell

γδ T-cell lymphomas: a homogeneous entity?

2000 ◽  
Vol 36 (4) ◽  
pp. 294-305 ◽  
Author(s):  
De Wolf-Peeters ◽  
Achten
Keyword(s):  
T Cell ◽  
Γδ T Cell ◽  
T Cell Lymphomas

Graft-Vs-Lymphoma (GVL) Induction with Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Primary Cutaneous T Cell Lymphomas (CTCL).

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 4574-4574
Author(s):  
Vikram R Paralkar ◽  
Sunita Dwivedy Nasta ◽  
Kelly Morrissey ◽  
Jacqueline Smith ◽  
Pavel Vassilev ◽  
...  
Keyword(s):  
T Cell ◽  
Research Funding ◽  
Survival Rates ◽  
Allogeneic Transplantation ◽  
Treatment Modalities ◽  
Additional Patient ◽  
Gamma Delta ◽  
Hematopoietic Stem ◽  
T Cell Lymphomas ◽  
Active Disease

Abstract Abstract 4574 Background CTCLs are generally incurable with conventional therapies. In particular, advanced mycosis fungoides (MF), Sézary syndrome (SS) and gamma delta varieties of CTCL have poor survival rates and are often refractory to traditional chemotherapy. Allogeneic SCT may provide a GVL effect and improve outcomes for these patients. Methods A retrospective analysis was performed at the University of Pennsylvania to identify all patients with CTCL who underwent allogeneic transplantation. 12 patients were identified who were transplanted between 2004 to 2010. A chart review was performed to obtain data about demographics, diagnosis, staging, treatment, transplantation and outcomes. Results Median age at diagnosis was 49 yrs and M:F ratio was 5:7. Prior to transplantation, 4 had MF (stages IIB, IIIB, IVA1, IVB; 2 with nodal transformation), 4 had SS (one stage IVA1, three IVA2; 1 with nodal transformation), and 3 had gamma delta T-cell lymphoma (all T3b). Median time from diagnosis to transplantation was 3.3 yrs (range 0.5@02b97 yrs). Patients had received a median of 8 non-chemotherapy, and 2 chemotherapy-based treatment modalities before being transplanted. Only 3 patients were in complete remission (CR) at the time of conditioning and 9 had evidence of active disease. Reduced intensity conditioning (RIC) was used in 10 cases (Flu/Bu, Flu/Cy or Flu/Mel), and conventional myeloablative conditioning (Cy/TBI) was used in 2. GVHD prophylaxis consisted of calcineurin inhibitor and methotrexate in all patients. The median follow up for all pts is 6.6 months (range 1.4 to 37.1 months) and 11.2 months for surviving patients. All patients engrafted with an ANC >500 a median 13 days after SCT. Median donor chimerism at day 100 after SCT in 10 evaluable pts was 97%. 7 of 12 patients developed acute GVHD, 4 of whom had grade 3 GVHD. Two patients died within the first 100 days, from sepsis with active disease. At day 100, 7 of 10 evaluable patients were in CR, with an additional patient achieving CR shortly after; therefore transplant induced and maintained CR in 6 pts with active disease. 3 patients relapsed after achieving CR a median of 11.4 months (range 5.3–13.0 months) after SCT. 2 patients never achieved CR, and progressed within a month of transplantation. The median PFS for all pts was 31 wks, and 1 yr and 2 yr PFS were 48% and 32% without an obvious plateau. 2 year OS was 53% (Figure 1). Median OS is not reached. 6 patients have died from progression (5) and GVHD (1), 5 remain in CR and 1 is alive with active disease. Conclusion RIC SCT can provide long-term disease control in patients with advanced CTCL otherwise refractory to immunotherapy and chemotherapy. Given the limited TRM, consideration for earlier transplant should be given. Larger retrospective and ideally prospective studies will further define the role of allogeneic SCT in this disease. Disclosures: Rook: Therakos: Speakers Bureau; HY Biopharma: Consultancy. Kim:TenX: Research Funding; Biocryst: Research Funding; Genmab: Research Funding; Glouchester: Research Funding; Celgene: Research Funding; Eisai: Consultancy.

Unique racial patterns in rare T-cell lymphomas: A National Cancer Registry analysis from 2001 to 2015.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e19070-e19070
Author(s):  
Nishi Shah ◽  
Diego Adrianzen Herrera ◽  
Urvi Shah ◽  
Bhaskar Chandu Kolla ◽  
Gurbakhash Kaur ◽  
...  
Keyword(s):  
T Cell ◽  
Incidence Rate ◽  
Nk Cell ◽  
Cell Lymphoma ◽  
Cancer Registries ◽  
Cell Leukemia ◽  
Gamma Delta ◽  
Annual Percent Change ◽  
Incidence Trends ◽  
T Cell Lymphomas

e19070 Background: Peripheral T-cell lymphomas (PTCL) are a rare heterogenous group of lymphomas and modern studies on incidence patterns of PTCL are lacking. Methods: Using the National Program of Cancer registries (NPCR) database, which covers 99% of the US population, we aim to evaluate the incidence of PTCL according to age, race-ethnicity, and gender; and examine trends over time. We identified PTCL using ICD-O-3 codes and evaluated incidence trends from 2001 to 2015. Results: A total of 78722 PTCL cases were identified, the most common were Mycoses fungoides/Sezary syndrome (MF-SS), PTCL Not Otherwise Specified (NOS), and ALK+ Anaplastic Large Cell Lymphoma (ALK+ ALCL). The age-adjusted incidence rate was 2.1 per 100,000. Incidence of PTCL increased with age (6.7/100,000 in 80+years). PTCL was more common in males than females (incidence rate ratio [IRR] of 0.6, p<0.05). Most PTCL were more common in Non-Hispanic Blacks (NHB). Incidence rates of MF-SS, PTCL NOS, Hepatosplenic TCL (HSL) in NHB were 0.8, 0.8, and 0.02 per 100,000 [IRR 1.7, 1.8, 2.2, p<0.05] respectively which is approximately twice that of Non-Hispanic whites (NHW). Viral related PTCL like Adult T-cell Leukemia Lymphoma (HTLV), Angio-Immunoblastic T-cell Lymphoma [AITL] (EBV), Extranodal NK-TCL nasal type [ENK TCL] (EBV), NK cell leukemia (EBV) are higher in groups at highest predisposition such as NHB and Non-Hispanic Asian Pacific Islanders (NHAPI). Primary cutaneous (PC) gamma-delta TCL occurs exclusively in NHW at an incidence rate of 0.03 per 100,000. There was no increase in overall yearly incidence of PTCL over the study period (0.1%, p=NS) but the incidence increased in NHB (Annual Percent Change [APC] 1.4%, p <0.05). Incidence of ENK TCL and AITL increased in NHAPI (2.2% and 3.7%, respectively [p <0.05]). The incidence of ALK + ALCL, PC CD30+ TCL decreased (APC -4.2%, -2% [p≤0.05] respectively). Conclusions: This is the first study to show unique incidence patterns of PTCL namely higher incidence in males, African Americans (esp. MF, PTCL-NOS and HSL unaccounted for viral etiologies) and exclusivity of primary cutaneous gamma delta TCL in NHW. Further research is needed to understand these differences.

scholarly journals Hepatosplenic and Other γΔ T-Cell Lymphomas

2007 ◽  
Vol 127 (6) ◽  
pp. 869-880 ◽  
Author(s):  
Francisco Vega ◽  
L. Jeffrey Medeiros ◽  
Philippe Gaulard
Keyword(s):  
T Cell ◽  
Γδ T Cell ◽  
T Cell Lymphomas

scholarly journals Intestinal γδ T-cell lymphomas are most frequently of type II enteropathy-associated T-cell type

2013 ◽  
Vol 44 (6) ◽  
pp. 1131-1145 ◽  
Author(s):  
Amanda L. Wilson ◽  
Steven H. Swerdlow ◽  
Grzegorz K. Przybylski ◽  
Urvashi Surti ◽  
John K. Choi ◽  
...  
Keyword(s):  
T Cell ◽  
Type Ii ◽  
Γδ T Cell ◽  
Cell Type ◽  
T Cell Lymphomas

scholarly journals Differential Activation of V γ4V δ1 and V γ9V δ2 Cord Blood Derived Gamma Delta T Cells upon Exposure to EBV-Lcl and K562 Cells

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 2790-2790
Author(s):  
Jeremy Wee Kiat Ng ◽  
Joey Lai ◽  
Tony Kiat Hon Lim ◽  
William YK Hwang ◽  
Shang Li ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Cord Blood ◽  
Single Cell ◽  
Γδ T Cells ◽  
Rapid Expansion ◽  
Leukemia Cell Line ◽  
Γδ T Cell ◽  
Gamma Delta

Abstract Gamma-delta (γδ) T cells have emerged as a promising candidate for adoptive cellular immunotherapy. To harness and maximize the anti-leukemia properties of these cells, we sort to comprehensively profile the transcriptomic signatures and immune repertoire of in vitro expanded γδ T cell products. Given the reported diverse TCR γδ repertoire and naïve nature of γδ T cells found in human cord blood (CB γδ), we serially track the molecular and cellular changes in these cells upon activation in expansion cultures. Based on the established viral reactivities of γδ T cell as well as prior studies showing their cross reactivities against leukemia and cancer cells, we had previously shown that stimulating CB γδ with an irradiated EBV-LCL feeder cell-based rapid expansion protocol (REP) is capable of generating cell products with potent and specific cytotoxicity against human AML cells. In the present study, using single cell RNA sequencing (scRNA-seq) coupled with single cell TCR γδ repertoire analysis, we compared the transcription signatures between our REP expanded γδ T cell (REP γδ) and non-manipulated γδ T cells reported in literatures, showing the progressive acquisition of an adult PB derived γδ T cell (PB γδ)-like cell states. Time course analysis demonstrated complex T cell activation and maturation trajectories correlating with variable level of clonal induction throughout the course of in vitro expansion. At the end of expansion, the harvested REP γδ are predominantly of the V γ4V δ1 subtype. Nevertheless, upon exposing REP γδ to target leukemia cell line K562, outgrowth of other non-V γ4V δ1 as well as the semi-invariant V γ9V δ2 cells were observed. Taken together, our data shows that as CB γδ expand and differentiate in culture, they adopt an adult PB γδ-like program. More importantly, our data highlights the rich clonal composition of in vitro expanded CB γδ, with different clonotypes being variably activated upon exposure to different stimuli. Such characteristics can potentially overcome the challenges of cancer heterogeneity and cell persistence, with the potential of improving outcomes in cell immunotherapy. Disclosures No relevant conflicts of interest to declare.

scholarly journals Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus

Blood ◽  
1993 ◽  
Vol 81 (10) ◽  
pp. 2688-2695 ◽  
Author(s):  
P Kanavaros ◽  
MC Lescs ◽  
J Briere ◽  
M Divine ◽  
F Galateau ◽  
...  
Keyword(s):  
T Cell ◽  
Tumor Cells ◽  
Epstein Barr Virus ◽  
Nk Cell ◽  
Gamma Delta ◽  
Barr Virus ◽  
T Cell Lymphomas ◽  
T Cell Antigens ◽  
Ebv Dna ◽  
Epstein Barr

Recent evidence has shown that most nasal lymphomas (NL) are associated with a T-cell phenotype and are thus called nasal T-cell lymphomas (NTCL), but little information is available about the T-cell receptor (TCR) expression. The presence of Epstein-Barr virus (EBV) genome has been recently reported in NTCL in Oriental populations in which NL and EBV-associated tumors are more common and in occasional Occidental cases. This prompted us to investigate lymphoma biopsies from 7 non- Oriental patients with NTCL for the expression of natural killer (NK) and T-cell antigens, including TCR proteins, for the presence of EBV- encoded latent membrane protein (LMP) using immunohistochemistry and for the presence of EBV DNA and Epstein-Barr early region (EBER) RNA using in situ hybridization (ISH). Six cases displayed a CD3-, TCR alpha beta-, TCR gamma delta-, CD2+, CD7+, CD5-, CD4-, CD8-, CD56+ phenotype, suggesting that these tumors may be peripheral T-cell lymphomas (PTCL) with extensive loss of T-cell antigens and expression of the NK-cell (CD56) antigen or, alternatively, NK-cell neoplasias. The remaining case was a gamma delta PTCL, as shown by the CD3+, TCR gamma delta+ phenotype and the biallelic gamma and delta TCR gene rearrangements. Using ISH, EBER RNA transcripts were detected in tumor cells in all cases and EBV DNA was shown in the 6 tested cases. In all cases, tumor cells expressed LMP. These findings support the concept that NTCL constitute a distinct group of lymphomas that, in addition to their peculiar clinical features, exhibit an unusual TCR “silent” CD56+ or TCR gamma delta+ phenotype and harbor the EBV. In view of the LMP transforming potential, these data suggest that EBV may play a role in the pathogenesis of NTCL.

Sign in / Sign up

Export Citation Format

Share Document